Targeting GBM: Novel Agent, Unique Mechanism

• Our technology fuses a tumor targeting nanobody to a modified highly active xanthine oxidase enzyme that generates localized production of high levels of reactive oxygen species, triggering immunogenic cell death and promoting immune cell recruitment.
• Our lead program, VISK-103, which targets EGFR, has demonstrated in vitro inhibition of select established and patient-derived GBM cell lines.
• VISK-103 inhibits tumor progression of mouse xenograft models including GBM with no preliminary evidence of toxicity.

Speakers:

Eric Fossel

Chief Executive Officer

Viska Bio